跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
3-Tyrosine
首页
药物
3-Tyrosine
Experimental
Small Molecule
3-Tyrosine
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
技术标识符
化学式
C
9
H
11
NO
3
CAS 编号
587-33-7
UNII ID
D5YF57V4QW
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBTOR
EP 4338738 A3
申请人: PHARMACYCLICS LLC
优先权: 2015
CN
EP
US
WO
21 件公开
Organic compounds
US 2006148058 A1
申请人: BARTHE CHRISTOPHE
优先权: 2002
US
12 件公开
ANTIBODIES TO FELINE MCDONOUGH SARCOMA (FMS)-LIKE TYROSINE KINASE 3 RECEPTOR LIGAND (FLT3L) AND USES THEREOF FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES
EP 3752195 A4
申请人: VIELA BIO INC
优先权: 2018
EP
US
WO
7 件公开
DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BRUTON S TYROSINE KINASE
EP 4529956 A3
申请人: HOFFMANN LA ROCHE
优先权: 2016
CN
EP
US
5 件公开
4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer
US 2008287475 A1
申请人: ASTRAZENECA AB
优先权: 2005
EP
US
5 件公开
FMS-LIKE TYROSINE KINASE 3 LIGAND (FLT3L)-BASED CHIMERIC PROTEINS
EP 3946409 A1
申请人: ORIONIS BIOSCIENCES INC
优先权: 2019
CN
EP
US
WO
4 件公开
PHARMACEUTICAL COMPOSITION FOR TREATING LEUKEMIA COMPRISING FLT3 INHIBITOR
US 20260102397 A1
申请人: HANMI PHARMACEUTICAL CO LTD
优先权: 2020
CN
EP
US
WO
4 件公开
Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
US 11787819 B2
申请人: MIRATI THERAPEUTICS INC
优先权: 2021
CN
US
WO
4 件公开
3-(Cycloalkanoheteroarylidenyl)-2-Indolinone Protein Tyrosine Kinase Inhibitors
US 2001056094 A1
申请人: TANG PENG CHO
优先权: 2000
US
4 件公开
Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3)
US 7365096 B2
申请人: UNIV TEXAS
优先权: 2003
US
4 件公开
第 1 / 10 页
上一页
下一页
药物
反馈